A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma

Trial Profile

A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Sargramostim
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2015 Planned End Date changed from 1 Feb 2013 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
    • 31 May 2013 Interim results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 15 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov. (Parent trial: NCT01134614).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top